Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005–2010 - Volume 21, Number 9—September 2015 - Emerging Infectious Disease journal - CDC
Volume 21, Number 9—September 2015
Emerging Infections Program
Emerging Infections Program
Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005–2010
Lyme disease (LD) is a zoonotic infection transmitted by Ixodes spp. ticks and caused by the spirochete Borrelia burgdorferi. Signs and symptoms of infection range in severity and can include erythema migrans, arthritis, facial palsy, radiculoneuropathy, arrhythmia, and meningitis. Most patients recover fully after antimicrobial treatment (1,2); however, serious illness and even deaths have been reported, although rarely (3–5). In the United States, LD is the fifth most commonly reported nationally notifiable disease; ≈36,000 confirmed and probable cases were reported in 2013 (6). US cases are concentrated heavily in the Northeast and upper Midwest (7).
Surveillance for LD in the United States is based on reports submitted by laboratories and health care providers to state and local health departments. These reports provide valuable insight into the age and sex distribution of patients with LD and the seasonality and geographic distribution of cases, and they enable monitoring of disease trends over time. Unfortunately, underreporting and variation in surveillance practices limit the ability of routine surveillance to capture the true overall frequency of LD within the population (8). Studies conducted during the 1990s in high-incidence states suggest that LD cases are underreported by a factor of 3 to 12 (9–12). These studies were limited to specific states and do not necessarily reflect underreporting nationwide.
Medical claims data provide an additional source of information about the epidemiology and public health importance of LD. Because these data are based on billing records submitted by clinicians for reimbursement, they are less prone to underreporting than are routine surveillance data that require additional documentation. We used information from a large, nationwide medical claims database to 1) describe the epidemiology of LD diagnosed by clinicians, 2) identify similarities and differences with surveillance data, and 3) estimate the number of LD cases per year in the United States.
Dr. Nelson is a medical epidemiologist at the Bacterial Diseases Branch, Division of Vector-Borne Diseases, CDC, Fort Collins, Colorado. Her primary research interests are the epidemiology and clinical manifestations of LD, Bartonella infections, tularemia, and plague.
We are extremely grateful to Julie Ray, Elizabeth Schiffman, Heather Rutz, Katherine Feldman, Joshua Clayton, Jennifer White, Nadia Thomas, David McClure, Carla Rottscheit, Edward Belongia, & Allison Naleway for retrieving and sharing additional archived data related to their studies. We thank C. Ben Beard for his assistance with initiating this study and Brian Dixon for helpful feedback on the manuscript. Finally, we thank Truven Health Analytics, Peter Hicks, and CDC’s Division of Health Informatics and Surveillance for facilitating access to and analysis of the MarketScan database.
- Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med. 2003;348:2472–4.
- Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med. 2002;136:421–8 .
- Centers for Disease Control and Prevention. Three sudden cardiac deaths associated with Lyme carditis—United States, November 2012–July 2013.MMWR Morb Mortal Wkly Rep. 2013;62:993–6 .
- Halperin JJ. Nervous system Lyme disease. Handb Clin Neurol. 2014;121:1473–83 .
- Rothermel H, Hedges TR, Steere AC. Optic neuropathy in children with Lyme disease. Pediatrics. 2001;108:477–81.
- Centers for Disease Control and Prevention. Final 2013 reports of nationally notifiable infectious diseases. MMWR Morb Mortal Wkly Rep.2014;63:702 .
- Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease—United States, 1992–2006. MMWR Surveill Summ. 2008;57:1–9 .
- Janes G, Hutwagner L, Cates W, Stroup D, Williamson G. Principles and practices of public health surveillance. 2nd ed. New York: Oxford University Press; 2000.
- Campbell GL, Fritz CL, Fish D, Nowakowski J, Nadelman RB, Wormser GP. Estimation of the incidence of Lyme disease. Am J Epidemiol.1998;148:1018–26.
- Coyle BS, Strickland GT, Liang YY, Pena C, McCarter R, Israel E. The public health impact of Lyme disease in Maryland. J Infect Dis.1996;173:1260–2.
- Meek JI, Roberts CL, Smith EV, Cartter ML. Underreporting of Lyme disease by Connecticut physicians, 1992. J Public Health Manag Pract.1996;2:61–5.
- Naleway AL, Belongia EA, Kazmierczak JJ, Greenlee RT, Davis JP. Lyme disease incidence in Wisconsin: a comparison of state-reported rates and rates from a population-based cohort. Am J Epidemiol. 2002;155:1120–7.
- Wormser GP, Dattwyler R, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis.2006;43:1089–134.
- Adams DA, Gallagher KM, Jajosky RA, Kriseman J, Sharp P, Anderson WJ, Summary of notifiable diseases—United States, 2011. MMWR Morb Mortal Wkly Rep. 2013;60:1–117 .
- National Notifiable Diseases Surveillance System. Lyme disease case definitions, 1995–2011 [cited 2015 Jun 28].http://wwwn.cdc.gov/nndss/conditions/lyme-disease/
- US Census Bureau. 2010 Census demographic profile summary file. 2011 [cited 2015 Jun 26]. http://www.census.gov/2010census/data
- Kim SY, Solomon DH, Liu J, Chang CL, Daniel GW, Schneeweiss S. Accuracy of identifying neutropenia diagnoses in outpatient claims data.Pharmacoepidemiol Drug Saf. 2011;20:709–13.
- Segal JB, Powe NR. Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study. Am J Hematol. 2004;75:12–7.
- Sickbert-Bennett EE, Weber DJ, Poole C, MacDonald PD, Maillard JM. Utility of International Classification of Diseases, Ninth Revision, Clinical Modification codes for communicable disease surveillance. Am J Epidemiol. 2010;172:1299–305.
- Rutz H, Hinckley A, Hogan B, Feldman K. Exploring the use of diagnostic codes as an alternative approach to Lyme disease surveillance in Maryland. 23rd Annual Conference of the Council of State and Territorial Epidemiologists: 2013 Jun 9–13; Pasadena (CA) [cited 2015 Jun 26].https://cste.confex.com/cste/2013/webprogram/Paper1901.html
- Clayton JL, Jones SG, Dunn JR, Schaffner W, Jones TF. Enhancing Lyme disease surveillance by using administrative claims data, Tennessee, USA.Emerg Infect Dis. 2015;21:1632–34.
- Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis. 2014;59:676–81.
- Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379:461–73 and.
- Miralles D, Hartman B, Brause B, Fisher L, Murray HW. Not everything that glitters is Lyme disease. Am J Med. 1992;93:352–3.
- Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA. 1993;269:1812–6 and.
- Robinson S. Lyme disease in Maine: a comparison of NEDSS surveillance data and Maine Health Data Organization hospital discharge data. Online J Public Health Inform. 2014;5:231.
- Bennet L, Stjernberg L, Berglund J. Effect of gender on clinical and epidemiologic features of Lyme borreliosis. Vector Borne Zoonotic Dis.2007;7:34–41.
- Strle F, Wormser GP, Mead P, Dhaduvai K, Longo MV, Adenikinju O, Gender disparity between cutaneous and non-cutaneous manifestations of Lyme borreliosis. PLoS ONE. 2013;8:e64110.
Suggested citation for this article: Nelson CA, Saha S, Kugeler KJ, Delorey MJ, Shankar MB, Hinckley AP, et al. Incidence of clinician-diagnosed Lyme disease, United States, 2005–2010. Emerg Infect Dis. 2015 Aug [date cited]. http://dx.doi.org/10.3201/eid2109.150417